Phase II Study of Bevacizumab and Pemetrexed for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

OBJECTIVE: To evaluate the efficacy and safety of combination bevacizumab/pemetrexed for the treatment of recurrent epithelial ovarian cancer (EOC). METHODS: Platinum-sensitive or -resistant patients with recurrent or persistent EOC were eligible if they had received up to 2 prior chemotherapy regim...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Hagemann, Andrea R., Novetsky, Akiva P., Zighelboim, Israel, Gao, Feng, Massad, L. Stewart, Thaker, Premal H., Powell, Matthew A., Mutch, David G., Wright, Jason D.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3939037/
https://ncbi.nlm.nih.gov/pubmed/24096113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2013.09.032
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky